F.D.A. Panel Recommends Approval of Hepatitis B Drug

http://query.nytimes.com/gst/abstract.html?res=F70617FE355F0C748CDDA10894DA404482
Business/Financial Desk | August 7, 2002, Wednesday
 

By ANDREW POLLACK (NYT) 579 words
Late Edition - Final , Section C , Page 3 , Column 1

ABSTRACT - FDA advisory committee unanimously recommends approval for Gilead Sciences drug adefovir for hepatitis B (S) A Food and Drug Administration advisory committee unanimously recommended approval yesterday for the Gilead Sciences drug adefovir for hepatitis B, a viral infection for which there are few good treatments.

If the F.D.A. follows the panel's recommendation, as it usually does, the once-a-day pill could be on the market by September, said John Milligan, senior vice president at Gilead, a biotechnology company in Foster City, Calif.